PERmixon® in LUTS Evaluation Study (PERLES)

NCT02121613 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

833

Enrollment

INDUSTRY

Sponsor class

Conditions

Benign Prostatic Hyperplasia (BPH)

Interventions

DRUG: Permixon® 160 mg
DRUG: Tamsulosine LP
DRUG: Placebo matching Permixon® 160 mg
DRUG: Placebo matching Tamsulosine LP

Sponsor

Pierre Fabre Medicament